A detailed history of Geode Capital Management, LLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,391,702 shares of VTYX stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,391,702
Previous 1,314,352 5.89%
Holding current value
$2.57 Million
Previous $3.04 Million 0.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.85 - $3.2 $143,097 - $247,520
77,350 Added 5.89%
1,391,702 $3.03 Million
Q2 2024

Aug 09, 2024

BUY
$2.31 - $5.59 $479,422 - $1.16 Million
207,542 Added 18.75%
1,314,352 $3.04 Million
Q1 2024

May 13, 2024

BUY
$1.9 - $10.13 $154,262 - $822,464
81,191 Added 7.92%
1,106,810 $6.09 Million
Q4 2023

Feb 13, 2024

BUY
$2.08 - $31.18 $103,602 - $1.55 Million
49,809 Added 5.1%
1,025,619 $2.53 Million
Q3 2023

Nov 13, 2023

BUY
$29.8 - $40.3 $5.96 Million - $8.06 Million
200,090 Added 25.79%
975,810 $33.9 Million
Q2 2023

Aug 11, 2023

BUY
$28.53 - $39.55 $6.81 Million - $9.44 Million
238,578 Added 44.42%
775,720 $25.4 Million
Q1 2023

May 15, 2023

BUY
$29.51 - $46.65 $818,253 - $1.29 Million
27,728 Added 5.44%
537,142 $18 Million
Q4 2022

Feb 13, 2023

BUY
$24.16 - $36.38 $2.43 Million - $3.65 Million
100,452 Added 24.56%
509,414 $16.7 Million
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $1.55 Million - $4.75 Million
122,759 Added 42.89%
408,962 $14.3 Million
Q2 2022

Aug 12, 2022

BUY
$11.95 - $18.75 $1.08 Million - $1.7 Million
90,551 Added 46.28%
286,203 $3.5 Million
Q1 2022

May 13, 2022

BUY
$10.0 - $19.98 $81,130 - $162,097
8,113 Added 4.33%
195,652 $2.65 Million
Q4 2021

Feb 11, 2022

BUY
$14.2 - $23.07 $2.66 Million - $4.33 Million
187,539 New
187,539 $3.72 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $105M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.